https://scholars.lib.ntu.edu.tw/handle/123456789/633225
標題: | Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis | 作者: | YI-WEN HUANG Qin, Albert Tsai, Chan Yen PEI-JER CHEN |
關鍵字: | chronic hepatitis B | chronic hepatitis C | chronic hepatitis D | clinical trial | interferon | ropeginterferon alfa-2b | 公開日期: | 1-六月-2022 | 卷: | 14 | 期: | 6 | 來源出版物: | Viruses | 摘要: | Ropeginterferon alfa-2b is a novel mono-pegylated and extra-long-acting interferon, being developed for the treatment of myeloproliferative neoplasm (MPN) and chronic viral hepatitis. It has a favorable pharmacokinetic profile and less frequent dosing schedule, i.e., once every two to four weeks, compared to conventional pegylated interferon products, which have multiple isomers and are administered weekly. It was approved for the long-term treatment of polycythemia vera, an MPN, and has been included in the NCCN clinical practice guidelines for this indication. Ropeginterferon alfa-2b has demonstrated efficacy and showed a favorable safety profile for the treatment of chronic viral hepatitis in several clinical studies. In this article, we review its pharmacokinetics and available clinical data and suggest that ropeginterferon alfa-2b administered once every two weeks can serve as a new treatment option for patients with chronic viral hepatitis, including chronic hepatitis B, C, and D. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633225 | ISSN: | 1999-4915 | DOI: | 10.3390/v14061128 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。